Aqilion and Merck partner to develop TAK1 protein inhibitors
Pharmaceutical Technology
FEBRUARY 16, 2023
Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.
Let's personalize your content